Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine.

[1]  A. Hoeft,et al.  Impact of CYP2D6 genotype on postoperative tramadol analgesia , 2003, Pain.

[2]  D. Greenblatt,et al.  Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[3]  K. Brøsen,et al.  Impact of the CYP2D6 genotype on post‐operative intravenous oxycodone analgesia , 2010, Acta anaesthesiologica Scandinavica.

[4]  D. Hochstrasser,et al.  The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone , 2010, British journal of pharmacology.

[5]  M. Relling,et al.  Development and implementation of a pharmacist-managed clinical pharmacogenetics service. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[6]  J. Brockmöller,et al.  Effects of the CYP2D6 Gene Duplication on the Pharmacokinetics and Pharmacodynamics of Tramadol , 2008, Journal of clinical psychopharmacology.

[7]  S. Willmann,et al.  Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.

[8]  M. Dahl,et al.  Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. , 1997, Therapeutic drug monitoring.

[9]  Timothy J Kropp,et al.  Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. , 2011, Regulatory toxicology and pharmacology : RTP.

[10]  J. Ahlner,et al.  High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases , 2010, Clinical pharmacology and therapeutics.

[11]  E. Sellers,et al.  Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. , 1997, The Journal of pharmacology and experimental therapeutics.

[12]  F. Nielsen,et al.  The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. , 2009, Basic & clinical pharmacology & toxicology.

[13]  U. Hofmann,et al.  Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype , 1997, Clinical pharmacology and therapeutics.

[14]  G. Kearns,et al.  Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. , 1999, Pharmacogenetics.

[15]  A. Gabrielli,et al.  Codeine, Ultrarapid-Metabolism Genotype, and Postoperative Death , 2009 .

[16]  S. Kaasa,et al.  Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study , 2011, European Journal of Clinical Pharmacology.

[17]  L. Arendt-Nielsen,et al.  The hypoalgesic effect of tramadol in relation to CYP2D6 * , 1996, Clinical pharmacology and therapeutics.

[18]  A. Gaedigk,et al.  The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.

[19]  J. Gallinat,et al.  Association of CYP2D6 genotypes and personality traits in healthy individuals. , 2006, Journal of clinical psychopharmacology.

[20]  J Kirchheiner,et al.  Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication , 2007, The Pharmacogenomics Journal.

[21]  D. Hochstrasser,et al.  Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety , 2010, British journal of pharmacology.

[22]  E. Sellers,et al.  CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone , 1993, Clinical pharmacology and therapeutics.

[23]  A. Doehring,et al.  Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers , 2009, Pharmacogenetics and genomics.

[24]  B. Carleton,et al.  Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study , 2009, Clinical pharmacology and therapeutics.

[25]  V. Rollason,et al.  Pharmacogenetics of analgesics: toward the individualization of prescription. , 2008, Pharmacogenomics.

[26]  T. Tephly,et al.  The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[27]  U. Ekblad,et al.  Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation , 2003, Clinical pharmacology and therapeutics.

[28]  G. Koren,et al.  Guidelines for maternal codeine use during breastfeeding. , 2009, Canadian family physician Medecin de famille canadien.

[29]  Gideon Koren,et al.  Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother , 2006, The Lancet.

[30]  Mellar P. Davis,et al.  Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy , 2003, Supportive Care in Cancer.

[31]  M. Eichelbaum,et al.  Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation , 1998, Pain.

[32]  A. Doehring,et al.  Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? , 2009, PAIN®.

[33]  E. Kharasch,et al.  Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites , 2006, Clinical pharmacology and therapeutics.

[34]  Zeruesenay Desta,et al.  Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients , 2010, Journal of clinical pharmacology.

[35]  U. Wille,et al.  Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. , 1995, Life sciences.

[36]  M. Wadelius,et al.  Induction of CYP2D6 in pregnancy , 1997, Clinical pharmacology and therapeutics.

[37]  A. Hoeft,et al.  Concentrations of Tramadol and O‐desmethyltramadol Enantiomers in Different CYP2D6 Genotypes , 2007, Clinical pharmacology and therapeutics.

[38]  C. Regårdh,et al.  Pregnancy‐induced increase in metoprolol metabolism , 1985, Clinical pharmacology and therapeutics.

[39]  Y. Daali,et al.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.

[40]  T. Thum,et al.  A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. , 2003, Metabolism: clinical and experimental.

[41]  T. Muders,et al.  Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. , 2008, Anesthesia and analgesia.

[42]  M. Burns,et al.  Case-Control Study , 2020, Definitions.